Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sorrento Therapeutics, Inc.    SRNE

SORRENTO THERAPEUTICS, INC.

(SRNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dave & Buster's, Carnival fall; Sorrento, Herman Miller rise

share with twitter share with LinkedIn share with facebook
09/17/2020 | 05:25pm EDT

NEW YORK (AP) — Stocks that moved heavily or traded substantially Thursday:

Veeva Systems Inc., down $4.87 to $263.20.

The cloud-based software provider, which focuses on the life sciences industry, is considering becoming a public benefit company.

Moderna Inc., down 95 cents to $67.89.

The biotechnology company announced new collaborations and is expanding commercial operations outside of North America.

51job Inc., up $11.30 to $79.42.

The human resources services company said it received a buyout offer from DCP Capital Partners.

Herman Miller Inc., up $8.66 to $34.55.

The office furniture company handily beat Wall Street's first-quarter profit forecasts and reestablished its dividend.

Perrigo Co., down $1.46 to $48.38.

The generic drug developer expects a hefty charge as it recalls albuterol inhalers because of a defect.

Dave & Buster's Entertainment Inc., down $4.99 to $14.12.

The restaurant and arcade chain warned that it faces bankruptcy if it can't make a deal with lenders, according to the Wall Street Journal.

Sorrento Therapeutics Inc., up $1.12 to $9.48.

The biotechnology company received U.S. clearance to start an early study of a potential COVID-19 treatment.

Carnival Corp., down 22 cents to $16.24.

The cruise line extended the cancellation of some of its cruises, including routes in the Caribbean, until early 2021.

Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News


Stocks mentioned in the article
ChangeLast1st jan.
CARNIVAL CORPORATION & PLC 1.12% 15.36 Delayed Quote.-69.78%
DAVE & BUSTER'S ENTERTAINMENT, INC. -0.15% 20.45 Delayed Quote.-49.09%
HERMAN MILLER, INC. 3.54% 34.81 Delayed Quote.-16.42%
SORRENTO THERAPEUTICS, INC. -2.42% 8.08 Delayed Quote.139.05%
VEEVA SYSTEMS INC. 2.10% 296.85 Delayed Quote.111.04%
share with twitter share with LinkedIn share with facebook
All news about SORRENTO THERAPEUTICS, INC.
10/20SORRENTO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submiss..
AQ
10/16SORRENTO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8..
AQ
10/15SORRENTO THERAPEUTICS : Brazilian Health Regulatory Agency Authorizes Sorrento T..
AQ
10/14SORRENTO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
10/14SORRENTO THERAPEUTICS : Brazilian Health Regulatory Agency (ANVISA) Authorizes S..
AQ
10/14Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics'..
GL
10/13SORRENTO THERAPEUTICS : adds Mesenchymal Stem Cell Program That Has Been Cleared..
AQ
10/13SORRENTO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other ..
AQ
10/12Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a..
GL
10/12SORRENTO THERAPEUTICS : Adds Mesenchymal Stem Cell Program (MSC) That Has Been C..
AQ
More news
Financials (USD)
Sales 2020 58,7 M - -
Net income 2020 -179 M - -
Net Debt 2020 - - -
P/E ratio 2020 -9,73x
Yield 2020 -
Capitalization 2 054 M 2 054 M -
Capi. / Sales 2020 35,0x
Capi. / Sales 2021 5,96x
Nbr of Employees 310
Free-Float 81,9%
Chart SORRENTO THERAPEUTICS, INC.
Duration : Period :
Sorrento Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SORRENTO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 30,00 $
Last Close Price 8,08 $
Spread / Highest target 271%
Spread / Average Target 271%
Spread / Lowest Target 271%
EPS Revisions
Managers
NameTitle
Henry H. Ji Chairman, President & Chief Executive Officer
Stephen L Klincewicz VP-Pharmacovigilance & Clinical Operations
Najjam Asghar Chief Financial & Accounting Officer
Kim D. Janda Director
Jaisim Shah Director
Sector and Competitors
1st jan.Capitalization (M$)
SORRENTO THERAPEUTICS, INC.139.05%2 054
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097